News Sentiment

AUTL sentiment intelligence

Autolus Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.61 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.9% over one week, +3.2% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.9% Price digesting
Trend fit Trend active 3.2% over four weeks
Fair value -44.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 40
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
Stock Titan 16
TradingView 9
simplywall.st 5
TradingKey 3
Moomoo 2
Intellectia AI 1
www.marketscreener.com 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 22
Analyst action 5
Regulatory and legal 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
TradingKey Direct company coverage

Autolus Therapeutics PLC (AUTL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Autolus Therapeutics PLC (AUTL) has an earnings forecast score of 8.73, ranking 68th in its industry, with an average analyst price target of $10.00. Analysts largely recommend a "Buy" for the stock, forecasting next quarter's revenue at $30.24M and EPS at -$0.23. The previous qu

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 02:09
Source
TradingKey
Insider Monkey Direct company coverage

Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds

Autolus Therapeutics (AUTL) is moving beyond speculative status as its drug AUCATZYL (obe-cel) generates significant revenue. The company reported $26.2 million in net product revenue for AUCATZYL in Q1, up from $9.0 million year-over-year, and expects 2026 revenue to be between

Tone
Positive 75/100
Event
Earnings
Published
17 Jun 2026 11:16
Source
Insider Monkey